Compare TH & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | ANAB |
|---|---|---|
| Founded | 1978 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2017 | 2015 |
| Metric | TH | ANAB |
|---|---|---|
| Price | $13.72 | $62.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $13.00 | ★ $74.64 |
| AVG Volume (30 Days) | ★ 968.5K | 601.6K |
| Earning Date | 05-18-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,635,000.00 | $234,603,000.00 |
| Revenue This Year | $12.19 | N/A |
| Revenue Next Year | $35.63 | $31.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $5.97 | $15.40 |
| 52 Week High | $14.13 | $68.39 |
| Indicator | TH | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 83.11 | 55.41 |
| Support Level | $7.95 | $43.67 |
| Resistance Level | N/A | $67.69 |
| Average True Range (ATR) | 0.58 | 4.07 |
| MACD | 0.46 | -0.57 |
| Stochastic Oscillator | 94.35 | 60.16 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).